Pacira BioSciences, Inc. (PCRX)
| Market Cap | 1.45B +36.4% |
| Revenue (ttm) | 746.16M +5.7% |
| Net Income | 14.64M |
| EPS | 0.35 |
| Shares Out | 39.86M |
| PE Ratio | 103.22 |
| Forward PE | 11.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,690,149 |
| Open | 36.33 |
| Previous Close | 36.39 |
| Day's Range | 36.31 - 36.36 |
| 52-Week Range | 18.80 - 36.46 |
| Beta | 0.25 |
| Analysts | Hold |
| Price Target | 33.57 (-7.55%) |
| Est. Earnings | Nov 5, 2026 |
About PCRX
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for PCRX stock is "Hold." The 12-month stock price target is $33.57, which is a decrease of -7.55% from the latest price.
News
Pacira price target raised to $36.50 from $25 at RBC Capital
RBC Capital raised the firm’s price target on Pacira (PCRX) to $36.50 from $25 and keeps a Sector Perform rating on the shares after the company agreed to be acquired…
Pacira downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Pacira (PCRX) to Neutral from Buy with a price target of $36.50, down from $38. after the company agreed to be acquired by Viatris (VTRS) for $36.50…
Pacira downgraded to Hold from Buy at Truist
Truist downgraded Pacira (PCRX) to Hold from Buy with a price target of $36.50, up from $31, after the company agreed to be acquired by Viatris (VTRS) for $36.50 per…
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Pacira BioSciences, ...
Why Is Pacira Pharmaceuticals Stock (PCRX) Up 44% Today?
Pacira Pharmaceuticals stock rallied over 44% on Thursday alongside news of a merger agreement with Viatris.
Pacira downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Pacira (PCRX) to Perform from Outperform after the company agreed to be acquired by Viatris (VTRS) for $36.50 per share in cash.
Pacira downgraded to Hold from Buy at Jefferies
Jefferies downgraded Pacira (PCRX) to Hold from Buy with an unchanged price target of $36 after the company reached an agreement to be acquired by Viatris (VTRS) for $36.50 per…
Pacira upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded Pacira (PCRX) to Neutral from Underweight with a $36.50 price target after Viatris (VTRS) agreed to acquire the company for $36.50 per share in cash. The firm has…
Pacira downgraded to Hold from Buy at Needham
Needham downgraded Pacira BioSciences (PCRX) to Hold from Buy after Viatris (VTRS) agreed to acquire all of the outstanding shares of common stock for $36.50 per share in cash. Published…
Viatris to Buy Pacira BioSciences for $1.65 Billion
Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.
Viatris to acquire Pacira for $36.50 per share in cash, or $1.65B
07:45 EDT Viatris (VTRS) to acquire Pacira (PCRX) for $36.50 per share in cash, or $1.65B
Viatris to acquire Pacira for $36.50 per share in cash, or $1.65B
Viatris (VTRS) and Pacira BioSciences (PCRX) announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock…
Viatris to buy pain therapy maker Pacira Biosciences for $1.65 billion
Viatris said on Thursday it will buy Pacira Biosciences for $1.65 billion, adding the pain therapy maker's products to its portfolio.
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructur...
Pacira price target raised to $31 from $30 at Truist
Truist raised the firm’s price target on Pacira (PCRX) to $31 from $30 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home
Caregivers say they need clearer pain management plans, earlier education, and practical support on non-opioid options before a loved one undergoes surgery BRISBANE, Calif., Oct. 07, 2026 (GLOBE NEWSW...
Pacira, Molteni Farmaceutici to expand postsurgical pain management access
Pacira (PCRX) announced a strategic partnership with Molteni Farmaceutici to expand access to opioid-sparing postsurgical pain management across European markets. Through this partnership, Molteni Far...
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
– Expands patient access to opioid-sparing pain control and advances 5x30 strategy – BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader i...
Pacira initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Pacira (PCRX) with an Outperform rating and $32 price target The firm believes Exparel is entering a “stronger commercial phase.” Expanding separate reimbursement, ou...
Pacira initiated with a Market Perform at Leerink amid ‘formulary inertia’
As previously reported, Leerink analyst Daniel Clark initiated coverage of Pacira (PCRX) with a Market Perform rating and $28 price target The setup for Exparel has improved with the enactment…
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of pat...
Pacira initiated with a Market Perform at Leerink
Leerink initiated coverage of Pacira (PCRX) with a Market Perform rating and $28 price target
Pacira reinstated with a Buy at Truist
Truist analyst Anish Nikhanj reinstated coverage of Pacira (PCRX) with a Buy rating and $30 price target The company is positioned for “reliable and steadily” growing cash flows from Exparel,…
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —
Pacira price target raised to $25 from $24 at RBC Capital
RBC Capital analyst Douglas Miehm raised the firm’s price target on Pacira (PCRX) to $25 from $24 and keeps a Sector Perform rating on the shares.